Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Aims For 14 New Blockbuster Drugs By End Of 2017

This article was originally published in The Pink Sheet Daily

Executive Summary

At an investor day presentation Nov. 8, Novartis discussed a pipeline expected to yield 18 regulatory decisions over the next 24 months. The Swiss pharma currently has 139 ongoing pipeline projects, including 73 NMEs.

You may also be interested in...



As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology

The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.

Afinitor's Pancreatic Tumor Indication Limited To Progressive Disease

FDA approval of Novartis' everolimus for progressive pancreatic neuroendocrine tumors is in line with the Oncologic Drugs Advisory Committee's recommendations that the drug be reserved for those patients with more serious disease.

Go-Ahead For Appointment Of European Union Reference Labs For IVDs

EURLs have been a critical missing element of the IVDR for assessing the higher-risk class D IVDs. Two new implementing regulations, on fees and tasks, bring them closer to designation.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS073598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel